Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melinta’s lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.
Events & Presentations
Aug 07, 2018
Melinta Therapeutics Q2 2018 Earnings Call
Jun 20, 2018
Melinta Therapeutics, Inc. at the JMP Securities Life Sciences Conference
Jun 06, 2018
Melinta Therapeutics, Inc. at the Jefferies 2018 Global Healthcare Conference